{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "The provided text does not contain information on the adjusted EBITDA for the Degree Program Segment and the Alternative Credential Segment for 2022 and 2023. It does, however, define adjusted EBITDA (loss) and explains its use as a key metric to evaluate the company's operating performance.", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "From 2022 to 2023, the level of impairment charges for goodwill decreased in both the Degree Program Segment and Alternative Credential Segment.\n\n- Degree Program Segment: $0 in 2022 vs. $62.8 million in 2023 (as a result of impairment charges for the Alternative Credential reporting unit).\n- Alternative Credential Segment: $79.5 million in 2022 vs. $62.8 million in 2023 (the charge was attributed to the Alternative Credential reporting unit in 2023).", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "According to the provided text, FCE enrollments decreased in both segments:\n\n* Degree Program Segment: FCE enrollments decreased by 39,061, or 16.7%.\n* Alternative Credential Segment: FCE enrollments decreased, but the exact percentage is not specified. However, it is mentioned that FCE enrollments for boot camp offerings decreased by 6% and FCE enrollments for executive education offerings increased by 8%.", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": "The main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021, were:\n\n1. Divestitures ($33.5 million)\n2. Cost inflation\n3. Supply chain pressures\n4. Lower sales volumes in the dental market\n5. Inflationary cost pressures\n6. Negative impact of foreign exchange ($24.1 million)", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": "According to the chunks, the impairment charges on property and equipment decreased from $788 in 2021 to $18 in 2022. The amortization expense related to intangible assets, however, increased from $45,613 in 2021 to $48,695 in 2022, which was a decrease in net carrying value of intangible assets, while the total value of intangible assets actually increased by $49,759.", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "The operating income for Healthcare Solutions decreased from $69,358 in 2021 to $25,812 in 2022, a decrease of $43,546. The operating income for Industrial Solutions increased from $48,555 in 2021 to $22,837 in 2022, a decrease of $25,718.", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "The question cannot be answered as the provided chunks do not mention interest income from customer funds.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "In the fourth quarter of 2023, Block, Inc. reorganized its business structure and moved the BNPL platform's business activities, management, and financial results from the Square segment to the Cash App segment. This change is reflected in the segment results for the year ended December 31, 2023.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "According to the provided chunks, the classification and allowance for credit losses related to consumer receivables changed as follows:\n\n* Classified consumer receivables as a percentage of total amortized cost decreased from 11.9% (0.1 billion / 0.843 billion) on December 31, 2022 to 3.8% (0.1 billion / 2.629 billion) on December 31, 2023.\n* The allowance for credit losses increased from $151.29 million on January 31, 2022 to $185.28 million on December 31, 2023.\n* The provision for credit losses increased from $203.67 million on January 31, 2022 to $261.30 million on December 31, 2023.\n* Charge-offs and other adjustments decreased from $168.66 million on January 31, 2022 to $228.85 million on December 31, 2023.", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "According to the consolidated balance sheet in chunk 1, the net property and equipment value increased from $159,432 on December 31, 2022, to $144,718 on December 31, 2023, resulting in a decrease of $14,714 or -9.2%.", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "Based on the provided chunks, the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements are:\n\n1. Adjusted gross profits and adjusted gross profit margin, which are non-GAAP financial measures that are useful in measuring the company's ability to source, add value, and sell services and products provided by third parties.\n2. Revenue recognition, particularly for transportation and logistics services, where revenue is recognized as the performance obligations are satisfied over the contract term.\n3. Goodwill impairment testing, where the company elected to bypass the Step Zero Analysis and perform a Step One Analysis on all reporting units, resulting in no impairments recorded in any period presented.\n4. Income tax reserves, where the company establishes reserves for uncertain tax positions and recognizes benefits when it is more likely than not that the position will be sustained upon audit.\n5. Changes in expected volatility and risk-free interest rates, which affect the discount used in estimating the fair value of stock options.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "According to chunk 0, the amount of revenue recognized for contracts where the transit period was partially complete declined significantly at December 31, 2023 compared to December 31, 2022, driven by macroeconomic and industry factors impacting the cost of purchased transportation.", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "According to the financial statement, the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231,312.\n\nAs of December 31, 2023, the unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million, which is significantly higher than the total stock-based compensation expense for the year.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "According to the provided chunks:\n\n* Research and development expenses increased by $32.5 million from 2022 to 2023.\n* Sales and marketing expenses decreased by $32.5 million from 2022 to 2023, reversing the increase seen in research and development expenses.\n\nThe main reasons for these changes were:\n\n* Research and development expenses increased due to an increase in personnel expenses and facility and support services to support ongoing clinical trials and research efforts.\n* Sales and marketing expenses decreased due to a realignment of the sales force, decreases in advertising spend, costs incurred under the promotion agreement with Pfizer, and fewer costs incurred on commercial related information technology projects.", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporationâ€™s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "According to the consolidated statement of cash flows, Exact Sciences Corporation's cash and cash equivalents at the end of 2023 was $605,378, up from $242,790 at the beginning of the year. This increase of $362,588 was due to net cash provided by operating activities of $156.1 million and net cash provided by financing activities of $159.8 million, partially offset by a decrease in cash provided by investing activities of $24.4 million.", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "Esperion's net product sales increased by $22.4 million from 2022 to 2023. Their collaboration revenue increased by $18.4 million within the same period.", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc.'s net loss decreased from $233,659 in 2022 to $209,248 in 2023. The main factors contributing to this decrease were:\n\n* A decrease in operating expenses (from $254,976 to $271,897)\n* An increase in other income, net (from $2,652 to $5,291)\n* A decrease in interest expense (from $56,810 to $58,976)\n\nThese changes resulted in a decrease in the net loss of $24,411.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "Here are the changes in net product sales and collaboration revenue from 2022 to 2023:\n\n* Net product sales of NEXLETOL and NEXLIZET increased by $22.4 million from $55.9 million in 2022 to $78.3 million in 2023.\n* Collaboration revenue increased by $18.4 million from $19.6 million in 2022 to $38.0 million in 2023.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "Unfortunately, the text does not provide the 2021 revenue data for either the Property & Casualty insurance vertical or the Health insurance vertical.", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "In the year ended December 31, 2023, Open Marketplace transactions accounted for $378,730 of revenue, while Private Marketplace transactions accounted for $214,708 of revenue.", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue was $60,132, which was 26.8% of the $224,366 in P&C insurance revenue for the year ended December 31, 2022. This decline in P&C insurance revenue was a significant contributor to the overall decline in total revenue, which decreased by $70,923, or 15.4%, to $388,149 in 2023.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "According to the provided chunks, potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations include:\n\n* Reduced data exclusivity period from 8 years to 6 years, potentially affecting the company's ability to maintain market exclusivity for its products.\n* Changes to the regulatory framework for medical devices, potentially impacting the company's ability to commercialize its product candidates that are classified as medical devices.\n* Increased regulatory burdens and uncertainty due to the UK's departure from the EU and the introduction of new regulations, potentially delaying marketing approval or affecting post-approval activities.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "$0.2 million was not issued, but $99.8 million remained available for issuance under the shelf registration statement, of which $40.0 million (not $59.8 million, as of December 31, 2023, $40.0 million) is reserved for sales under the ATM, and $59.8 million is the amount available but not yet reserved for sales under the ATM.", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "Potential consequences include:\n\n* Significant fines, penalties, and administrative sanctions\n* Convictions, settlements, and disgorgement of profits\n* Cessation of business activities, divestiture, or prison time\n* Negative impact on reputation, ability to conduct business, financial position, operating results, profitability, or liquidity\n* Impairment of the company's ability to generate revenue, including commercialization of its product candidates\n* Limitations on operations, including clinical trials, in jurisdictions where controlled substances are not approved or allowed.", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "According to the text, sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, which was attributable to the Compute & Networking segment.\n\nThis concentration poses the challenge of potential loss of a significant portion of revenue if the customer decides to cancel, change, or delay product purchases. Additionally, this concentration increases the risk that NVIDIA's operating results may be adversely affected if the customer is lost or if NVIDIA is unable to sell to them.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "NVIDIA's net income increased from $4,368 million to $29,760 million from January 29, 2023, to January 28, 2024. This represents a 583% increase.\n\nRevenue increased from $26,974 million to $60,922 million over the same period, a 125% increase. Net income growth far exceeded revenue growth.", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "13% of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, referred to as Customer A.\n\nThis demonstrates a risk presented in the Risk Factors, which states that the Company's revenue is expected to remain concentrated in the Compute & Networking segment. A high percentage of revenue coming from a single customer increases the risk that the Company's revenue and profitability may be negatively impacted if that customer were to decrease its purchases or cease doing business with the Company.", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": "According to the provided chunks, Paratek's financial position affected their ability to utilize net operating loss carryforwards after the merger as follows:\n\n* The merger resulted in an ownership change, subjecting Transcept's pre-merger net operating loss carryforwards to limitations under Section 382 of the Internal Revenue Code.\n* As a result, Transcept's net operating loss carryforwards and certain other tax attributes are subject to limitations on their use after the merger.\n* The Company conducted an analysis under Section 382 and 383 of the Internal Revenue Code and identified certain net operating losses that might expire unused.\n* The Company established a full valuation allowance against these attributes, indicating that they do not expect to utilize a material portion of their net operating loss carryforwards.\n\nThe impact on regulatory operations was not explicitly stated, but it can be inferred that the limitations on net operating loss carryforwards could have a material adverse effect on cash flow and results of operations.", "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": "According to the consolidated statements of operations and comprehensive loss, Paratek Pharmaceuticals' net product revenue for NUZYRA increased from $106,084 thousand in 2021 to $136,820 thousand in 2022, a year-over-year increase of $30,736 thousand or 29%.\n\nThe increase in net product revenue had a minimal impact on the company's net loss, as the net loss decreased from $59,084 thousand in 2021 to $63,566 thousand in 2022.", "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": "The factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements are:\n\n1. Ability to retain and train an adequate number of commercial personnel.\n2. Inability to deliver a consistent message regarding NUZYRA to physicians.\n3. Limited product line, putting the company at a competitive disadvantage.\n4. Unforeseen costs and expenses associated with maintaining an independent sales and marketing organization.\n5. Complications or barriers in reaching the appropriate audience due to the spread of COVID-19 or other contagious diseases.\n6. Success of collaborations with third parties for sales, marketing, and distribution services.\n7. Ability to secure sufficient starting materials and maintain commercial manufacturing arrangements with third-party manufacturers.\n8. Ability to produce sufficient quantities and inventory of NUZYRA to meet demand.\n9. Ability to secure widespread acceptance of NUZYRA from physicians, healthcare payors, patients, and the medical community.\n10. Ability to properly price and obtain coverage and adequate reimbursement of NUZYRA.", "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "According to chunk 1 and chunk 2, the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023 were:\n\n* Increase in deliveries year over year\n* Decrease in the average combined cost per unit of vehicles, due to:\n\t+ Sales mix\n\t+ Lower inbound freight\n\t+ Decrease in material costs\n\t+ Lower manufacturing costs from better fixed cost absorption\n* Decrease in average selling price of vehicles\n* Favorable impact from the United States dollar strengthening against foreign currencies\n* Favorable impact from IRA manufacturing credits earned during the year.", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "According to the information provided in chunk 2, Tesla's short-term investments changed from $22,185 million as of December 31, 2022, to $29,094 million as of December 31, 2023.", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "According to the provided chunks, the commitments for:\n\n* Capital expenditure in New York: $5.00 billion (through December 31, 2029)\n* Tax revenues in Shanghai: RMB 2.23 billion (starting at the end of 2023)", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
